Phalanx Rex

Informazioni principali

  • Nome commerciale:
  • Phalanx Rex
  • Forma farmaceutica:
  • SC sospensione concentrata
  • Utilizzare per:
  • Piante
  • Tipo di medicina:
  • Agrochimico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • Phalanx Rex
    Svizzera
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Erbicida

Altre informazioni

Status

  • Fonte:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Numero dell'autorizzazione:
  • W-4552-2
  • Ultimo aggiornamento:
  • 18-11-2018

Foglio illustrativo: composizione, posologia, indicazioni, interazioni, gravidanza, allattamento, effetti indesiderati, controindicazioni

Denominazione commerciale: Phalanx Rex

Elenco dei prodotti fitosanitari (stato: 06.11.2018)

Categoria di prodotti:

Titolare dell'autorizzazione:

Numero federale di omologazione:

Erbicida

Renovita AG

W-4552-2

Principio:

Tenore:

Codice di formulazione:

Principio attivo: Napropamide 42.2 % 450 g/l

SC sospensione concentrata

Applicazioni

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

B Fragola

Dicotiledoni annuali

(malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2.5 l/ha

Applicazione: Dopo la piantagione. In

autunno.

F Colza autunnale

Dicotiledoni annuali

(malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 3 l/ha

Applicazione: Autunno; incorporamento in

presemina; in pre-emergenza dopo la semina,

senza interramento.

F Tabacco

Dicotiledoni annuali

(malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2 l/ha

Applicazione: Primavera; prima o subito

dopo la piantagione.

Alberi e arbusti (al

di fuori della

foresta)

Dicotiledoni annuali

(malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2.5 l/ha

Caratterizzazione di pericolo:

Tenere fuori dalla portata dei bambini.

EUH 401 Per evitare rischi per la salute umana e per l'ambiente, seguire le istruzioni per l'uso.

H410 Molto tossico per gli organismi acquatici con effetti di lunga durata.

SP 1 Non contaminare l'acqua con il prodotto o il suo imballaggio.

Avvertenza:

Attenzione

Simboli e indicazioni di pericolo:

Identificatore chiave

GHS09

Simbolo

Indicazione di pericolo Pericoloso per l'ambiente acquatico

In caso di dubbio valgono soltanto i documenti originali dell'omologazione. La menzione di un prodotto,

principio attivo o di una ditta non rappresenta alcuna raccomandazione.

13-11-2018

Peer review of the pesticide risk assessment of the active substance napropamide‐M

Peer review of the pesticide risk assessment of the active substance napropamide‐M

Published on: Mon, 12 Nov 2018 00:00:00 +0100 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State the United Kingdom for the pesticide active substance napropamide‐M are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the representative uses of napropamid...

Europe - EFSA - European Food Safety Authority Publications

1-9-2018

Acknowledgement:EFSA  wishes  to  thank  the  rapporteur  Member  State  Denmark  for  thepreparatory work on this scientific output.Suggested citation:EFSA (European Food Safety Authority), Brancato A, Brocca D, Carrasco Cabrera L,De Lentdecker C, Erdos

Acknowledgement:EFSA wishes to thank the rapporteur Member State Denmark for thepreparatory work on this scientific output.Suggested citation:EFSA (European Food Safety Authority), Brancato A, Brocca D, Carrasco Cabrera L,De Lentdecker C, Erdos

Published on: Fri, 31 Aug 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance napropamide. To assess the occurrence of napropamide residues in plants, processed commodities, rotational crops and livestock, EFSA considered the conclusions derived in the framework of Directive 91/414/EEC as well as the European authorisations reported by Member States (incl...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Review of the existing maximum residue levels for napropamide according to Article 12 of Regulation (EC) No 396/2005

Review of the existing maximum residue levels for napropamide according to Article 12 of Regulation (EC) No 396/2005

Published on: Fri, 24 Aug 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance napropamide. To assess the occurrence of napropamide residues in plants, processed commodities, rotational crops and livestock, EFSA considered the conclusions derived in the framework of Directive 91/414/EEC as well as the European authorisations reported by Member States (incl...

Europe - EFSA - European Food Safety Authority Publications

29-6-2018

Medicines Safety Update, Volume 9, Number 2, June 2018

Medicines Safety Update, Volume 9, Number 2, June 2018

Oral methotrexate dosing, medicines associated with a risk of neuropsychiatric adverse events, and clozapine and gastrointestinal effects

Therapeutic Goods Administration - Australia

20-3-2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

First-generation oral sedating antihistamines – use in children, Suvorexant (Belsomra) – next day effects, Desvenlafaxine (Pristiq) recommended dose, Miconazole and potential interaction with warfarin

Therapeutic Goods Administration - Australia

5-3-2012

Danish Pharmacovigilance Update, 16 February 2012

Danish Pharmacovigilance Update, 16 February 2012

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Risk of overdose with methotrexate in the treatment of rheumatoid arthritis as well as intensified monitoring of heart rate and blood pressure in connection with treatment with Gilenya.

Danish Medicines Agency

22-10-2018

Pemetrexed Hospira (Pfizer Europe MA EEIG)

Pemetrexed Hospira (Pfizer Europe MA EEIG)

Pemetrexed Hospira (Active substance: pemetrexed) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6971 of Mon, 22 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3970/T/14

Europe -DG Health and Food Safety

2-10-2018

Pemetrexed Pfizer (Pfizer Europe MA EEIG)

Pemetrexed Pfizer (Pfizer Europe MA EEIG)

Pemetrexed Pfizer (Active substance: pemetrexed) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6464 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4488/T/04

Europe -DG Health and Food Safety

10-7-2018

Pemetrexed Sandoz (Sandoz GmbH)

Pemetrexed Sandoz (Sandoz GmbH)

Pemetrexed Sandoz (Active substance: pemetrexed) - Centralised - Yearly update - Commission Decision (2018)4485 of Tue, 10 Jul 2018

Europe -DG Health and Food Safety

10-7-2018

Pemetrexed Fresenius Kabi (Fresenius Kabi Deutschland GmbH)

Pemetrexed Fresenius Kabi (Fresenius Kabi Deutschland GmbH)

Pemetrexed Fresenius Kabi (Active substance: pemetrexed) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4472 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3895/T/7

Europe -DG Health and Food Safety

4-7-2018

Mysimba (Orexigen Therapeutics Ireland Limited)

Mysimba (Orexigen Therapeutics Ireland Limited)

Mysimba (Active substance: naltrexone / bupropion) - PSUSA - Modification - Commission Decision (2018) 4347 of Wed, 04 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3687/PSUSA/10366/201709

Europe -DG Health and Food Safety

11-6-2018

Pemetrexed Accord (Accord Healthcare Limited)

Pemetrexed Accord (Accord Healthcare Limited)

Pemetrexed Accord (Active substance: pemetrexed) - Centralised - Yearly update - Commission Decision (2018)3761 of Mon, 11 Jun 2018

Europe -DG Health and Food Safety

28-5-2018

Armisarte (Actavis Group PTC ehf.)

Armisarte (Actavis Group PTC ehf.)

Armisarte (Active substance: pemetrexed) - Centralised - Yearly update - Commission Decision (2018)3348 of Mon, 28 May 2018

Europe -DG Health and Food Safety

25-5-2018

Skin cancer is the most preventable type of cancer. Avoiding sunburn and overexposure to the sun's ultraviolet rays is key:  https://survivorship.cancer.gov/springboard/wellness/sun-safety … #dontfrydaypic.twitter.com/1vzXm28tQC

Skin cancer is the most preventable type of cancer. Avoiding sunburn and overexposure to the sun's ultraviolet rays is key: https://survivorship.cancer.gov/springboard/wellness/sun-safety … #dontfrydaypic.twitter.com/1vzXm28tQC

Skin cancer is the most preventable type of cancer. Avoiding sunburn and overexposure to the sun's ultraviolet rays is key: https://survivorship.cancer.gov/springboard/wellness/sun-safety … #dontfryday pic.twitter.com/1vzXm28tQC

FDA - U.S. Food and Drug Administration

24-5-2018

Jylamvo (Therakind Ltd)

Jylamvo (Therakind Ltd)

Jylamvo (Active substance: methotrexate) - PSUSA - Modification - Commission Decision (2018)3263 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2014/201706

Europe -DG Health and Food Safety

24-5-2018

Pemetrexed Krka (KRKA, d.d., Novo mesto)

Pemetrexed Krka (KRKA, d.d., Novo mesto)

Pemetrexed Krka (Active substance: pemetrexed) - Centralised - Authorisation - Commission Decision (2018)3278 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3958

Europe -DG Health and Food Safety

18-5-2018

Nordimet (Nordic Group B.V.)

Nordimet (Nordic Group B.V.)

Nordimet (Active substance: methotrexate) - PSUSA - Modification - Commission Decision (2018)3155 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2014/201706

Europe -DG Health and Food Safety

15-5-2018

Pemetrexed Fresenius Kabi (Fresenius Kabi Oncology Plc.)

Pemetrexed Fresenius Kabi (Fresenius Kabi Oncology Plc.)

Pemetrexed Fresenius Kabi (Active substance: pemetrexed) - Centralised - Yearly update - Commission Decision (2018)3060 of Tue, 15 May 2018

Europe -DG Health and Food Safety

15-5-2018

Pemetrexed Hospira (Hospira UK Limited)

Pemetrexed Hospira (Hospira UK Limited)

Pemetrexed Hospira (Active substance: pemetrexed) - Centralised - Yearly update - Commission Decision (2018)3059 of Tue, 15 May 2018

Europe -DG Health and Food Safety

13-4-2018

Comunicazione EMA su medicinali contenenti metotrexato (13/04/2018)

Comunicazione EMA su medicinali contenenti metotrexato (13/04/2018)

L’Agenzia Europea dei Medicinali ha avviato una revisione dei medicinali contenenti metotrexato, utilizzati per il trattamento tumori come la leucemia linfoblastica acuta (LLA) e altre condizioni infiammatorie, tra cui l'artrite reumatoide, l'artrite idiopatica giovanile, la psoriasi e l'artrite psoriasica.

Italia - AIFA - Agenzia Italiana del Farmaco

23-3-2018

Pending EC decision:  Pemetrexed Krka, pemetrexed, Opinion date: 22-Mar-2018

Pending EC decision: Pemetrexed Krka, pemetrexed, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency